CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma

Diffuse large B-cell lymphoma (DLBCL) exhibits significant genetic heterogeneity which contributes to drug resistance, necessitating development of novel therapeutic approaches. Pharmacological inhibitors of cyclin-dependent kinases (CDK) demonstrated pre-clinical activity in DLBCL, however many sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Thieme, Elana, Bruss, Nur, Sun, Duanchen, Dominguez, Edward C., Coleman, Daniel, Liu, Tingting, Roleder, Carly, Martinez, Melissa, Garcia-Mansfield, Krystine, Ball, Brian, Pirrotte, Patrick, Wang, Lili, Xia, Zheng, Danilov, Alexey V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061728/
https://www.ncbi.nlm.nih.gov/pubmed/36998071
http://dx.doi.org/10.1186/s12943-023-01762-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061728/
https://www.ncbi.nlm.nih.gov/pubmed/36998071
http://dx.doi.org/10.1186/s12943-023-01762-6

Ejemplares similares